NEW YORK (GenomeWeb) — Miacom Diagnostics and Fosun Diagnostics said today that they have partnered to market Miacom's molecular beacon-based diagnostic assays to the Chinese and broader Asian markets.
Under the agreement, Shanghai-based Fosun, the diagnostic division of Shanghai Fosun Pharmaceutical, will market Dusseldorf, Germany-based Miacom's proprietary multiplex assays for the detection of sepsis- and pneumonia-related pathogens.
Miacom's assays enable the identification of a wide variety of pathogens using molecular beacons and fluorescence in situ hybridization, according to its website. The company also said its tests use a proprietary sample-handling method, and that its assays can identify and differentiate various bacteria in 30 minutes.
Having Fosun Diagnostics as a partner "makes widespread distribution of our products in the Asian market feasible," Miacom CEO Mirko Stange said in a statement. "We believe that this partnership will further strengthen our position in other markets, as well."
Fosun Diagnostics is planning to build a US Food and Drug Administration-compliant, large-scale production facility that will dramatically reduce the production costs of Miacom's products and help the company move into the European and American markets, Miacom said.